Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012.

Autor:	de Hoyos-Alonso MC; Servicio Madrileño de Salud, Centro de Salud Pedro Laín Entralgo, Alcorcón, Madrid, España. Electronic address: mcanto.hoyos@salud.madrid.org., Tapias-Merino E; Servicio Madrileño de Salud, Centro de Salud Comillas, Área Centro, Madrid, España., Meseguer Barros CM; Servicio Madrileño de Salud, Subdirección General de Compras de Farmacia y Productos Sanitarios, Consejería de Sanidad, Comunidad de Madrid, España., Sánchez-Martínez M; Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España., Otero A; Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Neurologia (Barcelona, Spain) [Neurologia] 2015 Sep; Vol. 30 (7), pp. 416-24. Date of Electronic Publication: 2014 Apr 04.
DOI:	10.1016/j.nrl.2014.02.007
Abstrakt:	Introduction: Analysing drug consumption in large population groups lets us observe consumption trends and compare them between different settings. Objective: to analyse the time trends for consumption and costs of specific drugs used to treat dementia in the region of Madrid (Spain) and compare trends by sex and age cohort. Methods: Descriptive study of cholinesterase inhibitors (N06DA) and memantine (N06DX01) dispensed in Madrid between 2002 and 2012 and covered by the Spain's national health system. Consumption was calculated by analysing changes in DDD (defined daily doses) to find total and yearly increases. The cost was estimated based on DDD price. To compare consumption rates by age and sex, we calculated DDD per 100 inhabitants/day. Results: Between 2002 and 2012, consumption of drugs used to treat dementia increased sixfold. During this period, cholinesterase inhibitors accounted for 76.70% of the drugs consumed and memantine, 23.30%. The estimated cost rose by a by a factor of 5.7 over 11 years (or by a factor of 4 taking into account the use of generic drugs). In 2012, 2.42% of the patients aged 65 or over consumed cholinesterase inhibitors (women 2.82%, men 1.83%) and 0.90% consumed memantine (women 1.10%, men 0.61%). Consumption increased in age cohorts up to 86 to 90 (5.84% for cholinesterase inhibitors and 2.33% for memantine) and declined thereafter. Conclusions: Consumption of cholinesterase inhibitors and memantine gradually increased, but consumption in 2012 did not reach levels equivalent to dementia prevalence figures. Pharmaceutical expenditure restraint measures may temporarily slow the cost increase temporarily but if the same trend of consumption persists, costs will rise. (Copyright © 2013 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu